MTOR and adenocarcinoma: Since the mTOR pathway is upregulated in NSCLC, the concentration of p-mTOR increases by up to 90% in NSCLC patients with adenocarcinoma, and up to 60% and 40% in NSCLC patients with large cell carcinoma and squamous cell carcinoma (SCC), respectively [103].